New technologies and procedures for cervical cancer screening

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Cuzick, Jack ^a   Bergeron, Christine ^b   von Knebel Doeberitz, Magnus ^c   Gravitt, Patti ^d   Jeronimo, Jose ^e   Lorincz, Attila T ^a   M Meijer, Chris J L M ^f   Sankaranarayanan, Rengaswamy ^g   Snijders, Peter J F ^f   Szarewski, Anne ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LABORATOIRE CERBA   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e PATH   (United States)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervix cancer; HPV; HPV typing; Methylation; Screening; Self sampling; Visual inspection

Indexed keywords

ACETIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA TOPOISOMERASE (ATP HYDROLYSING); MINICHROMOSOME MAINTENANCE PROTEIN 2; VIRUS DNA; VIRUS PROTEIN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CELL CYCLE S PHASE; CHROMOSOME REPLICATION; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DNA METHYLATION; EMERGENCY HEALTH SERVICE; EPIGENETICS; FEMALE; FOLLOW UP; GENE SILENCING; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OPEN READING FRAME; PERSISTENT INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REVIEW; SCREENING TEST; SELF EVALUATION; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE; VIRUS TYPING; WART VIRUS;

EID: 84877013731     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.088     Document Type: Review

References (92)

1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010 Nov;11(11):1048-56.
2. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
3. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-88.
4. Berkhof J, Bulkmans NWJ, Bleeker MCG, Bulk S, Snijders PJF, Voorhorst FJ, et al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006;15(7):1268-73.
5. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, et al. HPV typespecific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007;97(1):129-32.
6. Castle PE, Stoler MH, Wright Jr TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12: 880-90.
7. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130(3):602-10.
8. Matsumoto K, Hirai Y, Furuta R, Takatsuka N, Oki A, Yasugi T, et al. Subsequent risks for cervical precancer and cancer in women with low-grade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy: results from a multicenter, prospective, cohort study. Int J Clin Oncol 2012;17(3):233-9.
9. Wright Jr TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206(1):46e1-11.
10. Wright Jr TC, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL, the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology- negative results. Am J Clin Pathol 2011;136:578-86.
11. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101(7):475-87.
12. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas C, Huh WK. Costeffectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecologic Oncology 2010;119:237-42.
13. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
14. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010;133:395-406.
15. Dijkstra MG, Heideman DA, de Roy SC, Rozendaal L, Berkhof J, van KK, et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010;63:972-7.
16. Zhang Q, Kuhn L, Denny LA, De SM, Taylor S, Wright Jr TC. Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 2007;120:351-6.
17. Negri G, Bellisano G, Zannoni GF, Rivasi F, Kasal A, Vittadello F, et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008;32:1715-20.
18. Ozaki S, Zen Y, Inoue M. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011;42:1007-12.
19. Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, Burk RD, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:1355-60.
20. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008;17:3033-42.
21. Denton K, Bergeron C, Klement P, Trunk T, Keller T, Ridder R, European CINtec Cytology Study Group. The sensitivity and specificity of p16INK4a cytology versus HPV testing for detecting High-Grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. Am J Clin Pathol 2010;134:12-21.
22. Schmidt D, Bergeron C, Denton K, Ridder R, for the European CINtec cytology study group. P16/Ki-67 dual-stained cytology in the triage of ASC-US and LSIL Pap cytology: results from the European equivocal or mildly abnormal Pap cytology study (EEMAPS). Cancer Cytopathol 2011;119:158-66.
23. Bergeron C, Schmidt D, Ikenberg H, Ridder R. High sensitivity and high specificity of p16/Ki-67 dual -stained cytology for high-grade CIN-results from screening and triage trials in over 28,000 women. Cancer Cytopathol 2010;118:305-6.
24. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol 2011;121: 505-9.
25. Carozzi F, Confortini M, Dalla PP, Del MA, Gillio-Tos A, De ML, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9:937-45.
26. Tambouret RH, Misdraji J, Wilbur DC. Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. Arch Pathol Lab Med 2008;132: 918-25.
27. Boucher J, Anku-Bertholet C, Temmar R, Pelmus M. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEx C, and p16INK4a/ProEx C in cervical squamous intraepithelial lesions. Hum Pathol 2009;40:904-5.
28. Walts AE, Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol 2009;40:957-64.
29. Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ. BDProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol Biomarkers Prev 2011;20:628-37.
30. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer 2008;114:83-8.
31. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597-610.
32. Lorincz AT. The promise and the problems of epigenetics biomarkers in cancer. Expert Opin Med Diagn 2011;5:375-9.
33. Vasiljevic N, Keqiang Wu P, Brentnall A, Kim DC, Thorat MA, Kudahetti SC, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011;30(4):151-61.
34. Bocklandt S, Lin W, Sehl ME, Sanchez FJ, Sinsheimer JS, Horvath S, et al. Epigenetic predictor of age. PLoS One 2011;6:1-6, e14821 e-pub.
35. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004 Feb 18;96(4):294-305.
36. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009 Feb;112(2):293-9.
37. Eijsink JJ, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, et al. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 2011 Feb;120(2):280-3.
38. Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011;129(9):2218-25.
39. Overmeer RM, Henken FE, Snijders PJ, Claassen-Kramer D, Berkhof J, Helmerhorst TJ, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008 Aug;215(4):388-97.
40. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, et al. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 2010 Sep 15;116(18):4266-74.
41. Wang SS, Smiraglia DJ, Wu YZ, Ghosh S, Rader JS, Cho KR, et al. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res 2008 Apr 1;68(7):2489-97.
42. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al. A four gene methylation marker panel as triage test in hr-HPV positive patients. Int J Cancer 2012;130(8):1861-9.
43. Hesselink AT, Heideman DA, Steenbergen RD, Coupé VM, Overmeer RM, Rijkaart D, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011 Apr 15;17(8): 2459-65.
44. Kalantari M, Calleja-Macias IE, Tewari D, Hagmar B, Lie K, Barrera-Saldana HA, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004;78: 12762-72.
45. Brandsma JL, Sun Y, Lizardi PM, Tuck DP, Zelterman D, Haines III GK, et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 2009;389:100-7.
46. Fernandez AF, Rosales C, Lopez-Nieva P, Gra{ogonek}na O, Ballestar E, Ropero S, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009;19:438-51.
47. Turan T, Kalantari M, Calleja-Macias IE, Villa LL, Cubie HA, Cuschieri K, et al. Methylation of the human papillomavirus-18 L1 gene: A biomarker of neoplastic progression? Virology 2006;349:175-83.
48. Piyathilake CJ, Macaluso M, Alvarez RD, Chen M, Badiga S, Edberg JC, et al. A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer 2011;117:957-63.
49. Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, et al. Methylation of the HPV16 genome is associated with disease progression in a prospective population-based cohort. J Natl Cancer Inst 2012 Apr 4;104(7):556-65.
50. Mu{ogonek}noz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-27.
51. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
52. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 2007 Oct;98(10):1505-11.
53. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006 May;110(5):525-41.
54. Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010 Dec;48(12): 4646-8.
55. Zhao FH. Performance of HPV E6 test for detection of cervical neoplasia. In: 27th International Papillomavirus Conference and Clinical Workshop. September 17-22. 2011.
56. Waller J, McCaffery K, Szarewski A, Cadman L, Austin J, Wardle J. Acceptability of unsupervised HPV testing by self-sampling using only written instructions. J Med Screening 2006;13(4):208-13.
57. Szarewski A, Cadman C, Ashdown-Barr L, Waller J. Exploring the acceptability of two self sampling devices for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in London. J Med Screen 2009;16:193-8.
58. Gravitt PE, Belinson JL, Salmeron J, Shah KV. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer 2011;129:517-27.
59. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-Mondragon E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011 Nov 26;378(9806): 1868-73.
60. Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, et al. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst 2012 Feb 8;104(3):178-88.
61. Lindell M, Sanner K, Wikstrom I, Wilander E. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG 2012;119:245-8.
62. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012;130(8):1855-60.
63. National Health Service. Cervical Screening Programme Annual Review 2006. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/cervical-annual-review-2006.pdf (last accessed June 2012).
64. Waller J, Bartoszek M, Marlow L, Wardle J. Barriers to cervical cancer screening attendance in England: a population-based survey. J Med Screen 2009;16(4):199-204.
65. Bais AG, van Kemenade FJ, Berkhof J, Verheijen RHM, Snijders PJF, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programmes. Int J Cancer 2007;120:1505-10.
66. Gök M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010 Mar 11;340:c1040.
67. Sanner K, Wikstrom I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009;101:871-4.
68. Wikström I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 2011 Jul 26;105(3):337-9.
69. Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikström I, Wilander E. Shorttime repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer 2011;105:694-7.
70. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer 2011 Mar 15;104(6):915-20.
71. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 2011 Jan 18;104(2):248-54.
72. Castle PE, Rausa A, Walls T, Gravitt PE, Partridge EE, Olivo V, et al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med 2011 Jun 1;52(6):452-5.
73. World Health Organization. Comprehensive Cervical Cancer Control: A guide to essential practice. Geneva: World Health Organization; 2006.
74. Sankaranarayanan R, Wesley RS. A practical manual on visual screening for cervical neoplasia. Lyon: International Agency for Research on Cancer; 2003.
75. Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet 2005;89(Suppl 2):S30-7.
76. Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011;113:14-24.
77. Sankaranarayanan R, Shastri SS, Basu P, Mahé C, Mandal R, Amin G, et al. The role of low-level of magnification with visual inspection with acetic acid in the early detection of cervical neoplasia. Cancer Detect Prev 2004;28(5):345-51.
78. Denny L, Kuhn L, Hu CC, Tsai WY, Wright Jr TC. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010;102:1557-67.
79. Kuhn L, Wang C, Tsai WY, Wright TC, Denny L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 2010;24:2553-61.
80. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398-406.
81. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
82. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-68.
83. Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer 2011;11:239.
84. Nessa A, Hussain MA, Rahman JN, Rashid MH, Muwonge R, Sankaranarayanan R. Screening for cervical neoplasia in Bangladesh with visual inspection with acetic acid. Int J Gynaecol Obstet 2010 Nov;111(2):115-8.
85. Tegute I, Muwonge R, Traore CB, Dolo A, Bayo S, Sankaranarayanan R. Can visual cervical screening be sustained in routine health services? Experience from Mali, Africa. BJOG 2012 Jan;119(2):220-6.
86. Dangou JM. Recommendations of the Ouagadougou regional consultative meeting on cervical cancer prevention and control in Africa. African Cancer Journal 2009;1:56-60.
87. Sankaranarayanan R, Nessa A, Esmy PO, Dangou JM. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2012 Apr;26(2):221-32.
88. Murillo R, Luna J, Gamboa O, Osorio E, Bonilla J, Cendales R, INC Cervical Cancer Screening Study Group. Cervical cancer screening with naked-eye visual inspection in Colombia. Int J Gynaecol Obstet 2010;109:230-4.
89. Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, et al. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004;110:907-13.
90. Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, et al. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 2006;119:1389-95.
91. Li R, Lewkowitz AK, Zhao FH, Zhou Q, Hu SY, Qiu H, et al. Analysis of the effectiveness of visual inspection with acetic acid/Lugol's iodine in one time and annual follow-up screening in China. Arch Gynecol Obstet 2012;285(6): 1627-32.
92. Lewis KC, Tsu VD, Dawa A, Kidula NA, Chami IN, Sellors JW. A comparison of triage methods for Kenyan women testing positive for cervical intraepithelial neoplasia by visual inspection of the cervix with acetic acid. Afr Health Sci 2011 Sep;11(3):362-9.